1. Ivashkin V. T., Mayev I. V., Lapina T. L., et al. Treatment of Helicobacter pylori infection: mainstream and innovations (Review of the literature and Russian gastroenterological association Advisory council resolution, May 19, 2017).Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(4):4-21. (In Russ.) doi: 10.22416/1382-4376-2017-27-4-4-21.@@ Ivashkin V. T., Maev I. V., Lapina T. L., Sheptulin A. A., Trukhmanov A. S., Abdulkhakov R. A., Alekseenko S. A., Dekhnich N. N., Kozlov R. S., Klyaritskaya I. L., Kurilovich S. A., Osipenko M. F., Simanenkov V. I., Khlynov I. B. Lechenie infektsii Helicobacter pylori: meinstrim i novatsii (Obzor literatury i rezolyutsiya Ekspertnogo soveta Rossiiskoi gastroenterologicheskoi assotsiatsii 19 maya 2017 g.). Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii. 2017;27(4):4-21. doi: 10.22416/1382-4376-2017-27-4-4-21.
2. Maev I. V., Samsonov A. A., Andreev D. N. et al. Clinical significance of Helicobacter pylori infection. Clinical Medicine. 2013; 8:4-12. (in Russ.)@@ Maev I. V., Samsonov A. A., Andreev D. N. i dr. Klinicheskoe znachenie infektsii Helicobacter pylori // Klinicheskaya meditsina. 2013; 8: 4-12.
3. Shey W.D., Leonitiadis G. I., Howden C. W., Moss S. F. ACG clinical guideline: treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017; 1123:212-38.
4. Tkach S.M., Onischuk L. A. Proton pump inhibitors and the risk of drug-drug interactions. Gastroenterology. 2015;2 (56):91-98. (in Russ.)@@ Tkach S. M., Onishchuk L. A. Ingibitory protonnoi pompy i risk mezhlekarstvennykh vzaimodeistvii Gastroenterologіya № 2 (56) • 2015 s 91-98.
5. Tolstokorov A.S., Dergunova S. A., Alexandrov D. A. The role of helicobacteriosis in the development of stomach diseases. Innovative science. 2019;(6):191-194. (in Russ.)@@ Tolstokorov A. S., Dergunova S. A., Aleksandrov D. A. Rol' khelikobakterioza v razvitii zabolevanii zheludka. Innovatsionnaya nauka № 6 / 2019 191-194